- Home
- CELU vs ATRA Comparison
CELU vs ATRA Comparison
Compare CELU & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | ATRA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 38.9M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CELU | ATRA |
|---|---|---|
| Price | $1.39 | $4.91 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | 108.3K | ★ 229.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | ★ N/A | $1.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $3.92 |
| 52 Week High | $4.35 | $19.15 |
Technical Indicators
Market Signals| Indicator | CELU | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 45.33 |
| Support Level | $1.16 | $4.70 |
| Resistance Level | $1.43 | $5.65 |
| Average True Range (ATR) | 0.07 | 0.43 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 87.21 | 38.54 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).